Bradley Monk, MD, Florida Cancer Specialists, West Palm Beach, Florida, discusses results from the phase 3 ROSELLA trial which assessed relacorilant plus nab-paclitaxel vs nab-paclitaxel alone in patients with platinum-resistant ovarian cancer. 

Study findings show that relacorilant plus nab-paclitaxel improves progression-free survival (PFS) and overall survival (OS), making it a potential new treatment option for these patients. 

Dr Monk presented these results at the 2025 ASCO Annual Meeting in Chicago, Illinois. 

Transcript: 

Greetings and welcome to ASCO. Chicago, yes, it's chaos, but I'm so happy to bring you the good news– the fifth dimension. 

Think of it, platinum-resistant, recurrent ovarian cancer. In fact, ovarian cancer, high-grade serious ovarian cancer, as a general theme is very difficult to treat and I, we, you, us brought chemotherapy, dimension 1. We, I, you brought bevacizumab, PARP inhibitors, antibody drug conjugates and what is the fifth dimension? A completely new mechanism of action, glucocorticoid receptor antagonism. Yes, cortisol is the stress hormone, it also induces resistance to chemotherapy so working with a sponsor, I, we, you we did a randomized phase 3 trial in 381 patients with platinum-resistant, recurrent ovarian cancer adding to the best treatment we have in that setting, hopefully to make it better. The best treatment in platinum-resistant, recurrent ovarian cancer is weekly taxane. Now we generally use paclitaxel, but paclitaxel requires steroids, and I just told you that glucocorticoid is the enemy of good. So, we needed a weekly taxane like nab-paclitaxel where it was not required to use dexamethasone. 

This is a randomized phase 3 trial called ROSELLA, called GOG-3073 and ENGOT-ov72, an international trial with our European friends, our GOG friends, and I didn't tell you my name is Brad Monk and I work at Florida Cancer Specialists and it's my honor to be affiliated with the GOG, it's my honor to enroll my patients on this trial, and my patients benefit when they go on clinical trials. And yes, the fifth dimension– this is a positive trial, this will likely be a practice changing trial that when added to weekly taxane in this setting nab-paclitaxel, relacorilant, a glucocorticoid receptor antagonist, help patients remain progression-free and live longer. That is a drop the mic moment. 

This will be presented at ASCO, the study's called ROSELLA, and it'll be presented by Alex Olawaiye a professor from Pittsburgh, and I invite you to look at the presentation, it's sensational. The hazard ratio for progression-free survival is 0.70, a 30% reduction in risk of progression and the hazard ratio for survival is 0.69, helping patients remain progression free and death free, that's why we do what we do. 

Greetings from ASCO, thank you for everything you're doing to help our patients and your patients by participating in clinical trials and hopefully you will have this opportunity in your patients soon, nab-paclitaxel, relacorilant in platinum-resistant, recurrent ovarian cancer. Thank you.

Source: 

Olawaiye A, Gladieff L, Gilbert L, et al. ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72). Presented at 2025 ASCO Annual Meeting. May 30-June 3, 2025; Chicago, IL. Abstract LBA5507